Short interest for agen, ensc, inab, xlo, zvsa, glue, allr, apdn

**Key takeaway 🏹** Among your eight biotech tickers, the *heaviest* short-crowding right now sits in Monte Rosa Therapeutics (GLUE 17 %) and Agenus (AGEN 12.7 %). The rest of the list carries only single-digit—or even sub-1 %—short exposure, so any “squeeze” narrative would need a fresh surge in bearish positioning or a sharp contraction in free float. | Ticker | Latest reported short-interest shares | % of float (if available) | Reporting date* | Quick read | |--------|--------------------------------------|---------------------------|-----------------|------------| | GLUE | 7,840,000 | **17.0 %** | 31 Oct 2024 | High absolute and relative SI; 3.8 days to cover suggest shorts could feel heat on a big catalyst | | AGEN | 2,241,148 | **12.70 %** | 25 Jul 2025 (FINRA tape) | Double-digit SI with 4.9 days to cover—watch clinical-data windows | | ZVSA | 49,600 | 4.7 % | 31 Aug 2024 | Tiny float means even ~50 k shares = material %, but days-to-cover only 0.4 | | ENSC | 689,400 | 6.3 % | 31 Aug 2024 | SI ballooned 3,885 % MoM last summer—bearish conviction has lingered | | ALLR | 1,720,000 | 6.7 % | 30 Jun 2024 | SI swung sharply higher in Q2; float is microscopic, so moves can be violent | | APDN | 2,140,000 | — (not disclosed) | 31 Aug 2024 | Raw shares elevated; % float not stated, but <3 days to cover keeps risk acute | | INAB | 389,700 | 1.3 % | 15 Jun 2024 | Bears are minimal here; volume-driven spikes more likely than squeeze | | XLO | 31,000 | 0.1 % | 31 Aug 2024 | Essentially no short crowding—squeeze dynamics unlikely | \*FINRA/Nasdaq publish short-interest snapshots twice monthly, normally settling on the 15th and month-end; public release follows about eight trading days later. --- ### How to use this info 🧭 1. **Catalyst overlay** • GLUE and AGEN enter conference season (SITC, ESMO) with elevated short stakes—positive data could force rapid covering. • ZVSA trades OTC (float thin, liquidity sporadic); even a modest headline can whiplash price because shorts have <½-day of typical volume to unwind. 2. **Float math matters** Absolute share counts can mislead—e.g., XLO’s 31 k shorts look tiny until you recall its float is >50 M shares, yielding a trivial 0.1 % SI. Focus on **% float and days-to-cover**, not just raw shares. 3. **Monitor the tape** Track off-exchange (“DF”) prints and borrow-fee spikes; a sudden jump in either often precedes the official SI report by days. 4. **Protect yourself** High-SI names can gap both ways. If you’re long: • Use **stop-loss buffers** wider than usual to survive volatility. • Size positions conservatively; borrow rates on GLUE, AGEN, ZVSA already run mid-single-digits (and can shoot >30 % overnight). --- ⚡ **Need deeper colour?** I can set up real-time alerts for borrow-fee changes, map FINRA off-exchange short-sale volume, or overlay these SI metrics with upcoming clinical milestones. Just say the word! 😊